New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has provided the ...

Researchers have long believed — and the authors of a new study hypothesized — that schizophrenics have lower brain levels of the neurotransmitter serotonin, and that those lower levels are associated ...

Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a ...

Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. With a successful series of early and mid-stage studies ...

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. The latest contender is Reviva Pharmaceuticals’ brilaroxazine, which reduced ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety ...

Scientists have identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. The study points to a potentially new target for ...

Genetic and environmental factors contribute to schizophrenia. Science has not yet determined how these two factors interact to produce the diverse array of behavioral and neurochemical changes in the ...